secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0000950170-23-056341
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio subleases 32,113 SF to Soleil Labs, terminates master lease by Dec 2024 with ~$36.7M in payments
--------------------------------------------------------------------------------

- Subleases 32,113 sq ft of its 85,165 sq ft facility to Soleil Labs for $183,044/mo (first 12 mos) then $189,451/mo, term through Dec 31, 2024.
- Enters First Amendment to Lease to terminate Master Lease on Dec 31, 2024; pays $15.9M prepaid rent and $20.8M termination fee.
- Surrenders all furniture and equipment to landlord upon termination; landlord returns letter of credit within 60 days.
- Company will have no further rent obligations post-Effective Date; Landlord may further accelerate termination for remaining space at $20K/month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023056341/0000950170-23-056341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023056341/grph-20231026.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-056341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer